Chrysenes for deep blue luminescent applications

This disclosure relates to chrysene compounds with deep blue emission that are useful in electroluminescent applications. It also relates to electronic devices in which the active layer includes such a chrysene compound.

Synthesis and applications of soluble pentacene precursors and related compounds

The present disclosure relates to methods and systems for synthesis of bridged-hydropentacene, hydroanthracene and hydrotetracene from the precursor compounds pentacene derivatives, tetracene derivatives, and anthracene derivatives. The invention further relates to methods and systems for forming thin films for use in electrically conductive assemblies, such as semiconductors or photovoltaic devices.

Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.

High Density Cyclic Fuels Derived From Linear Sesquiterpenes

A method to generate cyclic hydrocarbons from farnesene to increase both the density and net heat of combustion of the product fuels. The high density hydrocarbons produced by this method have applications for missile, UAV, jet, and diesel propulsion.

Glaucocalyxin a derivative and preparation method and application thereof

Provided is a glaucocalyxin A derivative, or salt thereof, as represented by the formula (I), a method for preparation of said glaucocalyxin A derivative, and a use for said glaucocalyxin A derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer

Spiroketal-Based C2-Symmetric Scaffold For Asymmetric Catalysis

Provided herein is a compound of formula (I): 4. The compound of claim 1 , wherein at least one X is OH.5. (canceled)6. The compound of claim 1 , wherein at least one X is PAr.7. (canceled)8. The compound of claim 1 , wherein at least one X is OPAr.9. (canceled)10. The compound of claim 1 , wherein at least one X is P(O)Ar.1112.-. (canceled)13. The compound of claim 6 , wherein Ar comprises phenyl.14. The compound of claim 1 , wherein both X together form OPNR′.1518.-. (canceled)19. The compound of claim 14 , wherein R′ is methyl.2022.-. (canceled)23. The compound of claim 1 , wherein R is ethyl.2428.-. (canceled)29. The compound of claim 1 , wherein at least one R is 3-10 membered heterocycloalkyl having 1-4 heteroatoms independently selected from N claim 1 , O claim 1 , and S.3034.-. (canceled)36. A catalyst comprising the compound of formula (I) according to and a transition metal.37. The catalyst of claim 36 , wherein the transition metal comprises iridium claim 36 , palladium claim 36 , rhodium claim 36 , platinum claim 36 , copper claim 36 , nickel claim 36 , cobalt claim 36 , or gold.38. A method of preparing the catalyst of comprising admixing the compound of formula (I) and the transition metal to form the catalyst.39. (canceled)40. The method of claim 38 , wherein the transition metal comprises [Ir(COD)Cl] claim 38 , [Pd(allyl)Cl] claim 38 , or Pd(dba).41. The method of claim 38 , wherein the compound of formula (I) and the transition metal are provided in a molar ratio of about 6:1 to 1:1.42. A method comprising:{'claim-ref': {'@idref': 'CLM-00036', 'claim 36'}, 'admixing a first reactant, a second reactant, and the catalyst of under conditions sufficient to allow reaction of the first reactant and the second reactant to form a reaction product, wherein the reaction product comprises a chiral center and the reaction produces an enantiomeric excess (ee) of the reaction product.'}43. The method of claim 42 , wherein the reaction comprises a hydroarylation ...

Low system memory detection

Methods, systems, and computer readable media may be operable to facilitate an anticipation of an execution of a process termination tool. An allocation stall counter may be queried at a certain frequency, and from the query of the allocation stall counter, a number of allocation stall counter increments occurring over a certain duration of time may be determined. If the number of allocation stall counter increments is greater than a threshold, a determination may be made that system memory is running low and that an execution of a process termination tool is imminent. In response to the determination that system memory is running low, a flag indicating that system memory is running low may be set, and one or more programs, in response to reading the flag, may free memory that is not necessary or required for execution.

BIFUNCTIONAL COMPOUND HAVING NORBORNANE SKELETON AND METHOD FOR PRODUCING SAME

The present invention is able to provide a bifunctional compound represented by formula (I). 112-. (canceled)14. The method according to claim 13 , wherein the catalyst having hydrogenation activity comprises at least one element selected from the group consisting of copper claim 13 , chromium claim 13 , iron claim 13 , zinc claim 13 , aluminium claim 13 , nickel claim 13 , cobalt and palladium.16. The method according to claim 15 , comprising performing the hydroformylation reaction using: the rhodium compound in an amount of 0.1 to 60 μmol relative to 1 mol of the monoolefin represented by formula (2); and the organic phosphorous compound in an amount of 300 to 10000 times the molar quantity of the rhodium compound. The present invention relates to a bifunctional compound useful as a paint additive, adhesive, resin raw material or the like and a method for producing the same, and particularly relates to a bifunctional compound having a norbornane skeleton in the molecule and a method for producing the same.It is known that a bifunctional compound having a norbornane skeleton exhibits excellent characteristics when used as an adhesive or resin raw material. As the bifunctional compound having a norbornane skeleton, tricyclodecane dicarbaldehyde and pentacyclopentadecane dicarbaldehyde are known, and several production methods have been reported (Patent Document 1).Patent Documents 2 to 4 describe that tricyclodecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen. Further, Patent Document 5 describes that tricyclodecane dicarbaldehyde or pentacyclopentadecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene or tricyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen.The tricyclodecane dicarbaldehyde described in Patent Documents 2 to 5 is a compound in which one norbornane and cyclopentane share a ...

Process For Preparing Pleuromutilin

The present disclosure provides processes for preparing (+)-pleuromutilin and synthetic (+)-pleuromutilin produced therefrom. Also provided are intermediates prepared thereby and processes for preparing these intermediates. 2. The process of claim 1 , wherein the organic solvent is a polar organic solvent.3. The process of claim 1 , wherein the organic solvent is an ethereal solvent.4. The process of claim 1 , wherein the organic solvent is tetrahydrofuran.5. The process of claim 1 , wherein the conditions are anaerobic.6. The process of claim 1 , wherein the organic solvent further comprises water.7. The process of claim 1 , comprising about 2.5 to about 3.5 moles of samarium(II) iodide per 1 mole of the compound of Formula I.8. The process of claim 1 , wherein the oxygen protecting group is methoxymethyl claim 1 , tetrahydropyranyl claim 1 , t-butyl claim 1 , allyl claim 1 , benzyl claim 1 , silyl claim 1 , acetyl claim 1 , pivaloyl claim 1 , trityl claim 1 , or benzoyl.9. The process of claim 1 , wherein the oxygen protecting group is methoxymethyl ether.11. The process of claim 10 , wherein Ris triphenyl methyl.12. The process of claim 10 , wherein the conditions effective to produce the compound of Formula IB comprise formic acid.13. The process of claim 10 , wherein the oxidizing conditions comprise a copper catalyst.14. The process of claim 13 , wherein the copper catalyst is [Cu(MeCN)]OTf or CuCu(OTf).16. The process of claim 15 , wherein the contacting is performed in an organic solvent under conditions sufficient to produce the compound of Formula III.17. The process of claim 16 , wherein the organic solvent is toluene.18. The process of claim 16 , wherein the temperature is about −10 to about 10° C.19. The process of claim 15 , wherein the diastereomeric excess of the compound of Formula III is at least 20%.22. The process of claim 21 , wherein the conditions sufficient to provide the compound of Formula VI comprise tris(2 claim 21 ,2 claim 21 ,6 claim 21 ...

Radiation-sensitive resin composition and resist pattern-forming method

A radiation-sensitive resin composition includes a polymer including a phenolic hydroxyl group, a compound represented by formula (1-1) or formula (1-2), and a compound represented by formula (2). In the formula (1-1), a sum of a, b, and c is no less than 1; at least one of R 1 , R 2 , and R 3 represents a fluorine atom or the like; and R 4 and R 5 each independently represent a hydrogen atom, a fluorine atom, or the like. In the formula (1-2), in a case in which d is 1, R 6 represents a fluorine atom or the like, and in a case in which d is no less than 2, at least one of the plurality of R 6 s represents a fluorine atom or the like; and R 8 represents a single bond or a divalent organic group having 1 to 20 carbon atoms.

PLEUROMUTILIN DERIVATIVE HAVING 2-AMINO PHENYL MERCAPTAN SIDE CHAIN AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF

A pleuromutilin derivative having a 2-amino phenyl mercaptan side chain as well as a preparation method and application thereof are provided. The derivative has a structure represented by formula 2 or formula 3, wherein, R1, R2 and R3 are each independently selected from a hydrogen atom, hydroxyl, amino, sulfydryl, hydroxymethyl, amine methyl, nitro, halogen, trihalogenated methyl, methyl, natural amino acid acylamino and C1-6 alkoxy. The plueuromutilin derivative in the disclosure has good activity of inhibiting drug-resistant and , and is especially suitable for preventing and treating infectious diseases caused by human or animal or drug-resistant or multidrug resistant bacteria as a novel antibacterial drug. 2. The pleuromutilin derivative according to claim 1 , wherein claim 1 , Ris one of hydrogen atom claim 1 , hydroxyl claim 1 , amino claim 1 , hydroxymethyl claim 1 , amine methyl claim 1 , fluorine claim 1 , trifuoromethyl claim 1 , nitro claim 1 , trifluoromethyl claim 1 , methoxy claim 1 , ethoxyl claim 1 , prolyl amino and valyl amino;{'sub': '2', 'Ris one of hydrogen atom, hydroxyl, amino, hydroxymethyl, amine methyl, fluorine, trifiuoromethyl, nitro, trifluoromethyl, methoxy, ethoxyl, prolyl amino and valyl amino; and'}{'sub': '3', 'Ris one of hydrogen atom, hydroxyl, amino, hydroxymethyl, amine methyl, fluorine, trifuoromethyl, nitro, trifluoromethyl, methoxy, ethoxyl, prolyl amino and valyl amino.'}3. The pleuromutilin derivative according to claim 1 , wherein claim 1 ,{'sub': 1', '2', '3, 'Ris methyl, Ris a hydrogen atom, and Ris a hydrogen atom;'}{'sub': 1', '2', '3, 'or Ris a hydrogen atom, Ris methyl, and Ris a hydrogen atom;'}{'sub': 1', '2', '3, 'or Ris a hydrogen atom, Ris a hydrogen atom, and Ris methyl;'}{'sub': 1', '2', '3, 'or Ris a fluorine atom, Ris a hydrogen atom, and Ris a hydrogen atom;'}{'sub': 1', '2', '3, 'or Ris a hydrogen atom, Ris a fluorine atom, and Ris a hydrogen atom;'}{'sub': 1', '2', '3, 'or Ris a hydrogen atom, Ris a ...

Small molecules active against gram-negative bacteria

Disclosed are compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.

POLYESTER RESIN AND PRODUCTION METHOD THEREFOR

A polyester resin according to the present invention comprises a constitutional unit represented by general formula (1): The present invention relates to a polyester resin and a production method therefor.Polyethylene terephthalate (hereinafter sometimes referred to as “PET”) is a polyester resin that is characterized by excellent transparency, mechanical strength, melt stability, solvent resistance, aroma retaining properties, and recyclability, and is widely utilized in film, sheet, hollow containers, and the like. However, it cannot be said that PET has a sufficiently high glass transition temperature, also transparency may be impaired due to its crystallinity when a thick molded, article is obtained, and therefore modification by copolymerization is widely carried out.For example, polyester resins are proposed in which 1,4-cyclohexanedimethanol, tricyclodecanedimethanol, or pentacyclopentadecanedimethanol is used as a copolymerization component for polyesters. Since tricyclodecanedimethanol and pentacyclopentadecanedimethanol have a bulky, rigid skeleton, polyester resins involving these have a high glass transition temperature, the crystallinity is suppressed, and it is thus possible to increase the transparency of a molded article (see, for example, Patent Literatures 1 and 2).On the other hand, among the aliphatic polyesters in which completely no aromatic components are used, polyesters with an alicyclic structure have excellent transparency and water resistance, and thus a large number of methods involving an alicyclic monomer represented by 1,4-cyclohexanedimethanol are proposed. For example, Patent Literature 3 discloses an aliphatic polyester composed of 1,4-cyclohexanedimethanol with 1,4-cyclohexanedicarboxylic acid or the like. Also, for increased heat resistance of aliphatic polyesters, polyesters having a norbornane skeleton are proposed (see, for example, Patent Literatures 4 and 5).The polyester resins described in Patent Literatures 1 and 2 are ...

13-OXIDIZED INGENOL DERIVATIVE AND USE THEREOF

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis. 2. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , prodrug claim 1 , metabolite or crystal form thereof claim 1 , wherein Ris selected from the group consisting of hydrogen and M-C(O)— claim 1 , wherein M is selected from the group consisting of linear alkyl and C-Clinear alkenyl.3. The compound of claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , prodrug claim 1 , metabolite or crystal form thereof claim 1 , wherein claim 1 , Ris selected from the group consisting of hydrogen and Q-C(O)— claim 1 , wherein Q is selected from the group consisting of C-Clinear alkyl claim 1 , C-Cbranched alkyl claim 1 , C-Clinear alkenyl claim 1 , C-Cbranched alkenyl claim 1 , 5-6 membered cycloalkyl claim 1 , phenyl claim 1 , 5-6 membered nitrogen-containing aliphatic heterocyclic group claim 1 , 5-6 membered heteroaryl claim 1 , 8-10 membered partially saturated nitrogen-containing fused heterocyclic group claim 1 , and NR′R″ claim 1 , wherein claim 1 , R′ is methyl group claim 1 , R″ is phenyl group optionally substituted with halogen(s); and in the 5-6 membered heteroaryl group claim 1 , the heteroatom is selected from the group consisting of nitrogen and oxygen;{'sub': 1', '5', '4', '5', '3', '5', '3', '5, 'optionally, the C-Clinear alkyl group, C-Cbranched alkyl group, C-Clinear alkenyl group or C-Cbranched alkenyl group is independently substituted with one or more phenyl groups, wherein the phenyl group is optionally substituted with methyl group(s);'}{'sub': 2', '3', '2, 'optionally, the 5-6 ...

FLUORINATING AGENT

An object of the present invention is to provide a novel substance that has a high reactivity as a fluorinating agent, is effectively used in various fluorination reactions, and is safely handled even in air. As the solution for achieving this object, the present invention provides a complex obtained by reacting bromine trifluoride with at least one metal halide selected from the group consisting of halogenated metals and halogenated hydrogen metals in a nonpolar solvent. This complex serves as a fluorinating agent that provides excellent fluorination performance and that is stable in air. 19-. (canceled)10. A method for fluorinating a compound , the method comprising:bringing the compound into contact with a complex consisting of bromine trifluoride and at least one metal halide selected from the group consisting of halogenated metals and halogenated hydrogen metals.11. The method according to claim 10 , wherein the complex exhibits an exothermic decomposition onset temperature in nitrogen of 40° C. or higher.12. The method according to claim 10 , wherein the complex is a reaction product obtained by mixing bromine trifluoride with at least one metal halide selected from the group consisting of halogenated metals and halogenated hydrogen metals claim 10 , in a nonpolar solvent.13. The method according to claim 12 , wherein the reaction product is obtained by reacting 0.5 mol or more of the metal halide claim 12 , per mol of bromine trifluoride.14. The method according to claim 10 , wherein the metal halide is at least one member selected from the group consisting of a halogenated metal represented by the formula: MX claim 10 , wherein M is Mor (M)1/2) claim 10 , Mis an alkali metal claim 10 , and Mis an alkaline earth metal claim 10 , and X is a halogen atom; and a halogenated metal represented by the formula: MHX claim 10 , wherein M and X are as defined above.15. The method according to claim 10 , wherein the metal halide is at least one potassium halide selected ...

Complex and structurally diverse compounds

The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp 3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.

Method of isolating ingenol

The present invention relates to a new method for isolating ingenol (C 20 H 28 O 5 ) from mixtures of diterpenoid esters and ingenol esters in a single step. Ingenol isolated by means of this method can be used as a precursor for the synthesis of biologically active ingenol derivatives, such as ingenol-3-angelate and ingenol-3-tigliate.

BENZODICYCLOALKANE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

It is provided herein a benzobicycloalkane derivative, and a preparation method and use thereof. In particular, it is provided herein a compound of Formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method, and a use thereof in preparation of drugs for treating pain. 2. The compound or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof of claim 1 , wherein Rand Rare hydrogen.3. The compound or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or stereoisomer thereof of claim 1 , wherein Ris hydrogen claim 1 , Calkyl claim 1 , Ccycloalkyl or —((CH)—O)—CH;{'sub': 2', '1-10', '3-8', '6-10', '2', 'n2', 'm2', '3, 'b': '13', 'Ris Calkyl, Ccycloalkyl, Caryl, 5 to 6 membered single heteroaryl ring, 4 to 6 membered saturated single heterocycle, spiro, spiroheterocycle, bridged ring, bridged heterocycle or —((CH) O)—CH; wherein n1 and n2 are each independently 2, 3 or 4; and, m1 and m2 are each independently 1, 2, 3, 4, 5, 6, 7, 8 or 9;'}{'sub': 1', '2, 'or Rand R, together with the nitrogen atom to which they are attached, form a 4 to 6 membered saturated single heterocycle; and'}{'sub': a0', 'b0', '1-8', '1-8', '1-8', '3-8', '3-8', '2-10', '2-10', '1-8', '6-10', '1-10', '1-10', '1-10', 'a0', 'b0', 'a0', 'b0', '1-8', '1-8', '1-8, 'the alkyl, cycloalkyl, aryl, 4 to 6 membered saturated single heterocycle, 5 to 6 membered single heteroaryl ring, spiro, spiroheterocycle, bridged ring, and bridged heterocycle are unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of NRR, halogen, acetyl, hydroxy, hydroxymethyl, hydroxyethyl, carboxyl, Calkyl, Calkoxy, halogenated Calkyl, Ccycloalkyl, Ccycloalkoxy, Calkenyl, Calkynyl, halogenated Calkoxy, Caryl, 4 to 6 membered saturated single heterocycle, —C(O)Calkyl, —C(O)OCalkyl, —OC(O)Calkyl, and —CONRR; and, Rand Rare each independently hydrogen, Calkyl, and Calkyl substituted with Calkoxy.'}4. The ...

Compound isolated from isodon forrestii var. forrestii and preparation method and applications thereof

A compound of Formula I or pharmaceutically acceptable salt thereof and its preparation method and applications, the new structure of the compound of formula I has not been reported in literature. It is isolated from Isodon forrestii var. forrestii and can be a compound served as Trx1 selective inhibitor. The present invention further discloses a pharmaceutical composition, preparation of the compound of Formula I and its applications in preparing medicines for preventing or treating cancer. Iso A of the present invention has the advantages of low toxicity, high safety and strong pharmacological effect, which suggests a potential prospect in pharmaceutical applications.

PSEUDO TRÖGER'S BASE AMINES AND MICROPOROUS POLYMERS DERIVED FROM PSEUDO TRÖGER'S BASE AMINES

Embodiments of the present disclosure describe carbocyclic pseudo Tröger's base (CTB) amines. Embodiments of the present disclosure further describe microporous polymers derived from pseudo CTB amines, including, but not limited to, polyimides, CTB ladder polymers, and network porous polymers. Other embodiments describe a method of separating chemical species in a fluid composition comprising contacting a microporous polymer membrane with a fluid composition including at least two chemical species, wherein the microporous polymer membrane includes one or more of a ladder polymer of intrinsic microporosity, a microporous polyimide, and a microporous network polymer; and capturing at least one of the chemical species from the fluid composition. 2. The diamine of claim 1 , wherein the halogens are selected from fluorine claim 1 , chlorine claim 1 , bromine claim 1 , and iodine.3. The diamine of claim 1 , wherein the alkyl groups are selected from methyl claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , butyl claim 1 , and iso-butyl.14. The method of claim 13 , wherein contacting includes one or more of feeding claim 13 , flowing claim 13 , and passing.15. The method of claim 13 , wherein the chemical species of the fluid composition includes one or more of O claim 13 , N claim 13 , H claim 13 , He claim 13 , CO claim 13 , C hydrocarbons claim 13 , olefins claim 13 , paraffins claim 13 , n-butane claim 13 , iso-butane claim 13 , butenes claim 13 , and xylene isomers.16. The method of claim 13 , wherein capturing includes removing one or more chemical species from the bulk fluid composition.17. The method of claim 13 , wherein the captured chemical species include one or more of O claim 13 , N claim 13 , H claim 13 , He claim 13 , CO claim 13 , C hydrocarbons claim 13 , olefins claim 13 , paraffins claim 13 , n-butane claim 13 , iso-butane claim 13 , butenes claim 13 , and xylene isomers.18. The method of claim 13 , wherein the microporous polymer membrane ...

Shelf life mass polymerizable polycycloolefin compositions as optical materials

Embodiments in accordance with the present invention encompass compositions encompassing a latent organo-ruthenium compound and a pyridine compound along with one or more monomers which undergo ring open metathesis polymerization (ROMP) when said composition is exposed to suitable actinic radiation to form a substantially transparent film. Surprisingly, the compositions are very stable at ambient conditions to temperatures up to 80° C. for several days and undergo mass polymerization when subject only to actinic radiation. Accordingly, compositions of this invention are useful in various opto-electronic applications, including as 3D printing materials, coatings, encapsulants, fillers, leveling agents, among others.

15-Oxospiramilactone Derivatives, Preparation Method and Uses Thereof

The invention relates to a derivative of 15-oxospiramilacton, particularly to a compound of Formula I or II, or an isomer, a solvate or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the compound as pharmaceutically active ingredient, a method for preparing the same, and use thereof in manufacture of an anti-tumor agent. The derivative of 15-oxospiramilactone of the invention have an activity against multiple tumor cell lines, and the anti-tumor activity is positively correlated to an activity inhibiting the Wnt signaling pathway.

Ingenol-3-acylates iii and ingenol-3-carbamates

The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

METHOD FOR PRODUCING BIFUNCTIONAL COMPOUND HAVING NORBORNANE SKELETON

The present invention provides a method for producing a bifunctional compound having a norbornane skeleton, the method comprising a step of hydroformylating a compound having an olefin with carbon monoxide and hydrogen, wherein the molar ratio of the carbon monoxide to the hydrogen during the reaction is 55/45 or more and 95/5 or less in the hydroformylating step. 3. The method of claim 1 , wherein the hydroformylating uses 0.1 to 60 micromoles of a rhodium compound per mole of the compound of formula (2) claim 1 , and 300 to 10000 moles of an organic phosphorus compound per mole of a rhodium atom in the rhodium compound. The present invention relates to a method for producing a bifunctional compound having a norbornane skeleton useful as coating additives, adhesives, starting materials of resin, and the like. Also, the present invention relates to a production method for preventing a monofunctional compound having a norbornane skeleton from being by-produced.It is known that a bifunctional compound having a norbornane skeleton exhibits excellent characteristics when used as adhesives or starting materials of resin. As a method for producing a bifunctional compound having a norbornane skeleton, for example, Patent Literature 1 describes that a bifunctional compound having a norbornane skeleton can be obtained through a hydroformylation reaction of a compound having a corresponding olefin.Patent Literature 1: International Publication No. WO 2015/147242A hydroformylation reaction is performed by reacting a compound having an olefin with an oxo gas, in presence of a catalyst containing rhodium or cobalt. The oxo gas for use as a starting material in the hydroformylation reaction is usually a gas having a controlled molar ratio between carbon monoxide and hydrogen of 50:50, because the hydroformylation reaction is represented by the following reaction formula. In the reaction between the oxo gas and the compound having an olefin, however, a certain amount of byproduct ...

BIFUNCTIONAL COMPOUND HAVING NORBORNANE SKELETON AND METHOD FOR PRODUCING SAME

The present invention is able to provide a bifunctional compound represented by formula (1). 111-. (canceled)13. The process as claimed in claim 12 , wherein Rin formula (3-a) and Rin in formula (3-b) represents H.14. The process as claimed in claim 12 , wherein Rin formula (3-a) and Rin in formula (3-b) represents CH.15. The process as claimed in claim 12 , wherein Rin formula (3-a) and Rin in formula (3-b) represents CH. The present invention relates to a bifunctional compound useful as a paint additive, adhesive, resin raw material or the like and a method for producing the same, and particularly relates to a bifunctional compound having a norbornane skeleton in the molecule and a method for producing the same.It is known that a bifunctional compound having a norbornane skeleton exhibits excellent characteristics when used as an adhesive or resin raw material. As the bifunctional compound having a norbornane skeleton, tricyclodecane dicarbaldehyde and pentacyclopentadecane dicarbaldehyde are known, and several production methods have been reported (Patent Document 1).Patent Documents 2 to 4 describe that tricyclodecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen. Further, Patent Document 5 describes that tricyclodecane dicarbaldehyde or pentacyclopentadecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene or tricyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen.The tricyclodecane dicarbaldehyde described in Patent Documents 2 to 5 is a compound in which one norbornane and cyclopentane share a plurality of atoms with each other to form the main skeleton as shown in formula (5) below. Further, the pentacyclopentadecane dicarbaldehyde described in Patent Document 5 is a compound in which two norbornanes and cyclopentane share a plurality of atoms with each other to form the main skeleton as ...

Diterpene production in yarrowia

The present invention relates to a method for the production of a diterpene or a glycosylated diterpene, which method comprises: a. fermenting a recombinant microorganism of the genus Yarrowia in a suitable fermentation medium at a temperature of about 29° C. or higher, wherein the microorganism comprises one or more nucleotide sequence(s) encoding: a polypeptide having ent-copalyl pyrophosphate synthase activity; a polypeptide having ent-Kaurene synthase activity; a polypeptide having ent-Kaurene oxidase activity; and a polypeptide having kaurenoic acid 13-hydroxylase activity and whereby expression of the nucleotide sequence(s) confer(s) on the microorganism the ability to produce at least steviol; and b. recovering the diterpene or glycosylated diterpene.

Synthesis of magnesium adamantane salts and magnesium oxide nanocomposites, and systems and methods including the salts or the nanocomposites

A method for preparing a magnesium adamantane carboxylate salt is provided. The method includes mixing a magnesium salt and a diamondoid compound having at least one carboxylic acid moiety to form a reactant mixture and hydrothermally treating the reactant mixture at a reaction temperature for a reaction time to form the magnesium adamantane carboxylate salt.

Method of producing ingenol-3-angelate

The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.

BIFUNCTIONAL COMPOUND HAVING NORBORNANE SKELETON AND METHOD FOR PRODUCING SAME

The present invention is able to provide a bifunctional compound represented by formula (1). 212-. (canceled)13. The bifunctional compound according to claim 1 , wherein Rrepresents COOCH.14. The bifunctional compound according to claim 1 , wherein Rrepresents COOCH.15. The bifunctional compound according to claim 1 , wherein Rrepresents COOCH.16. The bifunctional compound according to claim 1 , wherein Rrepresents COOCH.17. The bifunctional compound according to claim 1 , wherein Rrepresents CHO. The present invention relates to a bifunctional compound useful as a paint additive, adhesive, resin raw material or the like and a method for producing the same, and particularly relates to a bifunctional compound having a norbornane skeleton in the molecule and a method for producing the same.It is known that a bifunctional compound having a norbornane skeleton exhibits excellent characteristics when used as an adhesive or resin raw material. As the bifunctional compound having a norbornane skeleton, tricyclodecane dicarbaldehyde and pentacyclopentadecane dicarbaldehyde are known, and several production methods have been reported (Patent Document 1).Patent Documents 2 to 4 describe that tricyclodecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen. Further, Patent Document 5 describes that tricyclodecane dicarbaldehyde or pentacyclopentadecane dicarbaldehyde is obtained by hydroformylating dicyclopentadiene or tricyclopentadiene in the presence of a rhodium catalyst using a mixed gas of carbon monoxide and hydrogen.The tricyclodecane dicarbaldehyde described in Patent Documents 2 to 5 is a compound in which one norbornane and cyclopentane share a plurality of atoms with each other to form the main skeleton as shown in formula (5) below. Further, the pentacyclopentadecane dicarbaldehyde described in Patent Document 5 is a compound in which two norbornanes and ...

PYRENE DERIVATIVE, ORGANIC LIGHT-EMITTING MEDIUM, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING PYRENE DERIVATIVE OR ORGANIC LIGHT-EMITTING MEDIUM

An organic light-emitting medium including a pyrene derivative represented by the following formula (1) and a phenyl-substituted anthracene derivative represented by the following formula (2): 2. The organic light-emitting medium according to claim 1 , wherein Xto Xare a hydrogen atom.3. The organic light-emitting medium according to claim 1 , wherein Xand Xare a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms claim 1 , a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms or a substituted or unsubstituted cycloalkyl group having 3 to 20 ring carbon atoms claim 1 , and X claim 1 , Xto X claim 1 , Xand Xare a hydrogen atom.4. The organic light-emitting medium according to any of to claim 1 , wherein Arand Aris a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms.5. The organic light-emitting medium according to any of to claim 1 , wherein Rand R claim 1 , or Rand Rare a substituted or unsubstituted aryl group having 6 to 30 ring carbon atoms.6. The organic light-emitting medium according to or claim 1 , wherein Arand Arare a substituted or unsubstituted phenyl group.7. The organic light-emitting medium according to or claim 1 , wherein Rand R claim 1 , or Rand Rare a substituted or unsubstituted phenyl group.8. The organic light-emitting medium according to any of to claim 1 , wherein m is 1 and n is 1.9. The organic light-emitting medium according to any of to claim 1 , wherein m is 0 and n is 1.10. The organic light-emitting medium according to claim 8 , wherein Aris a substituted or unsubstituted arylene group having 6 to 18 ring carbon atoms or a substituted or unsubstituted heteroarylene group having 5 to 20 ring atoms claim 8 , Aris a substituted or unsubstituted aryl group having 6 to 18 ring carbon atoms or a substituted or unsubstituted heteroaryl group having 5 to 20 ring atoms.11. The organic light-emitting medium according to claim 9 , wherein Aris a substituted or unsubstituted aryl group ...

HIGH HEAT MONOMERS AND METHODS OF USE THEREOF

High heat monomer compounds, methods for preparing compounds, and compositions derived from the compounds are provided. Also provided are materials and articles derived from the compounds. 2. The compound of claim 1 , wherein the compound has formula (II).3. The compound of claim 1 , wherein the compound has formula (III).4. The compound of claim 1 , wherein the compound has formula (IV).5. The compound of claim 1 , wherein the compound has formula (VI).6. The compound of claim 1 , wherein the compound has formula (VII).7. The compound of claim 1 , wherein the compound has formula (VIII).8. The compound of claim 1 , wherein the compound has formula (IX).10. The compound of claim 1 , wherein the compound has a purity of 97% or greater claim 1 , as determined by high performance liquid chromatography.11. A curable composition comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) a compound according to ;'}(ii) optionally a curing promoter; and(iii) optionally an auxiliary co-monomer.12. The curable composition of claim 11 , wherein the curable composition comprising the auxiliary co-monomer; and the auxiliary co-monomer is selected from maleimide resins claim 11 , benzoxazine resins claim 11 , vinylbenzyl ether resins claim 11 , alkene-containing monomers claim 11 , alkyne-containing monomers claim 11 , arylcyclobutene resins claim 11 , perfluorovinyl ether resins claim 11 , or a combination thereof.13. The curable composition of claim 11 , wherein the curable composition comprising the curing promoter; and the curing promoter is an organic peroxide.14. The curable composition of claim 13 , wherein the organic peroxide is selected from cumene hydroperoxide claim 13 , 2 claim 13 ,5-dimethylhexane-2 claim 13 ,5-dihydroperoxide claim 13 , 2 claim 13 ,5-dimethylhexane-2 claim 13 ,5-dihydroperoxide claim 13 , α claim 13 ,α-bis(t-butylperoxy-m-isopropyl)benzene claim 13 , dicumyl peroxide claim 13 , di(trimethylsilyl)peroxide claim 13 , trimethylsilyl ...

New Pleuromutilin Antibiotic Compounds, Compositions and Methods of Use and Synthesis

The present invention is directed to novel pleuroniutilin antibiotic compounds, intermediates which are useful for making these novel amibioiic compounds and related methods and pharmaceutical compositions for treating pathogens, especially bacterial infections, including gram negative bacteria and synthesizing these compounds.

PLEUROMUTILIN 2-[(DIPHENYLMETHYL)THIO]ACETIC ACID ESTER WITH ANTI-DRUG RESISTANT BACTERIA ACTIVITY AND A METHOD OF PREPARING THE SAME

A compound with anti-drug resistant bacteria activity having the formula (I): 3. The method of claim 2 , wherein the reaction of the compound of formula (II) with the compound of formula (III) comprises the following steps:placing the compound of formula (II) and the compound of formula (III), in a molar ratio of 1:1 to 1:1.3, in a reactor;adding an organic solvent and a catalytic amount of triethylamine under nitrogen atmosphere to obtain a reaction mixture;heating the reaction mixture at 20-60° C. for 3-6 hours;extracting the reaction mixture with ethyl acetate to obtain a crude product; andpurifying the crude product on a silica gel fresh chromatography column with petroleum ether and ethyl acetate as an eluent to obtain the compound of formula (I).4. The method of claim 3 , wherein the organic solvent is toluene claim 3 , dichloromethane or N claim 3 ,N-dimethylformamide.5. The method of claim 4 , wherein the organic solvent is dichloromethane.6. The method of claim 3 , wherein the molar ratio of the compound of formula (II) and the compound of formula (III) is 1:1.1.7. The method of claim 3 , wherein the reaction mixture is heated at 25° C.8. The method of claim 3 , wherein the reaction mixture is heated for 5 hours.9. The method of claim 3 , wherein the eluent is petroleum ether:ethyl acetate=4:1.11. The method of claim 10 , wherein the reaction of the compound of formula (II) with the compound of formula (IV) comprises the following steps:{'sub': 6', '12', '41, 'placing the compound of formula (II), a catalyst, and an ionic liquid in a reactor under nitrogen atmosphere, the catalyst being 12-molybdosilicic acid hydrate (HMoOSi);'}adding the compound of formula (IV) to the reactor to form a reaction mixture;heating the reaction mixture at 20-50° C. for 4-8 hours;placing the reaction mixture in a separating funnel to separate a crude product;purifying the crude product by recrystallization in methanol to obtain the compound of formula (I); andrecycling the ...

Chrysene compounds for blue or green luminescent applications

This invention relates to chrysene compounds that are useful in electroluminescent applications and are capable of blue or green emission. It also relates to electronic devices in which the active layer includes such a chrysene compound.

PROCEDURE FOR MANUFACTURING INGENOL-3 ANGELAT

Process for the preparation of pleuromutilins

Electroluminescent device

본 발명은 특히 인광 화합물의 호스트로서 하기 화학식 I의 화합물을 포함하는 전자 소자, 특히 전계발광 소자에 관한 것이다. 호스트는 인광 물질과 함께 기능하여 전계발광 소자의 개선된 효율성, 안정성, 제조가능성 또는 스펙트럼 특징을 제공할 수 있다. [화학식 I] The present invention relates to an electronic device, particularly an electroluminescent device, comprising a compound of the general formula (I) as a host of a phosphorescent compound. The host may function with the phosphorescent material to provide improved efficiency, stability, manufacturability, or spectral characteristics of the electroluminescent device. (I)

Method of producing ingenol-3-angelate

FIELD: chemistry. SUBSTANCE: present invention relates to method of producing ingenol-3-angelate (I) from ingenol (II). Invention also relates to intermediate products used for synthesis of ingenol-3-angelate (I) from ingenol (II), and methods of producing said intermediate products. Method of producing ingenol-3-angelate (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8A-methanocyclopente[a]cycloprope[e]cyclodecen-6-yl ester 2-methyl-2(Z)-butenoic acid) of formula (I) from ingenol of formula (II) includes following steps: (a) reaction of one or both of hydroxyl groups in positions 5 and 20 ingenol with suitable hydroxyl protecting agents, which can be identical or different, to obtain compound of general formula (III) or (IV) in which R 1 represents hydrogen or hydroxyl protecting group and R 2 represents hydrogen or hydroxyl protecting group, provided that R 1 and R 2 simultaneously represent hydrogen, or in which D is hydroxyl protecting group, (b) esterification hydroxyl group in position 3 compounds (III) or (IV) to obtain compounds of general formula (V) or (VI), in which R 1 , R 2 and D have values given above, and (c) removing hydroxyl protecting groups R 1 or R 2 , or R 1 or R 2 , or the compounds (V) or (VI) to obtain ingenol-3-angelate of formula (I). EFFECT: method allows to produce end product with good output. 25 cl, 11 tbl, 29 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 586 975 C2 (51) МПК C07C 67/08 (2006.01) C07C 67/297 (2006.01) C07C 69/533 (2006.01) C07D 319/08 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2013107386/04, 08.07.2011 (24) Дата начала отсчета срока действия патента: 08.07.2011 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 27.08.2014 Бюл. № 24 (73) Патентообладатель(и): ЛЕО ЛЭБОРЕТЕРИЗ ЛИМИТЕД (IE) R U 20.07.2010 US 61/366,018 (72) Автор(ы): ХЕГБЕРГ Томас (DK), ...

신규한 에스테르 화합물

α위치에 불소 원자 또는 불소 원자를 갖는 알킬기가 치환되며 알콕시메틸기를 에스테르 측쇄에 도입한 아크릴산 에스테르는 신규하다. 아크릴산 에스테르로 부터 얻어진 폴리머는 투명성, 산 탈리성 및 기판 밀착성에 있어서 개선되고 리소그라피 미세가공용 화학 증폭 레지스트 조성물을 제제화 하기 위하여 사용된다. 아크릴산 에스테르, 리소그라피, 레지스트 조성물, 화학증폭

레지스트 조성물 및 레지스트 패턴 형성 방법, 그리고, 화합물 및 산 발생제

일반식 (bd1-1), (bd1-2) 또는 (bd1-3) 으로 나타내는 화합물을 함유하는 레지스트 조성물. 식 중, Rx 1 ∼ Rx 4 는, 탄화수소기 혹은 수소 원자를 나타내거나, 또는 상호 결합하여 고리 구조를 형성하고 있어도 된다. Ry 1 ∼ Ry 2 는, 탄화수소기 혹은 수소 원자를 나타내거나, 또는 상호 결합하여 고리 구조를 형성하고 있어도 된다. Rz 1 ∼ Rz 4 는, 탄화수소기 혹은 수소 원자를 나타내거나, 또는 상호 결합하여 고리 구조를 형성하고 있어도 된다. Rx 1 ∼ Rx 4 , Ry 1 ∼ Ry 2 및 Rz 1 ∼ Rz 4 중 적어도 1 개는 아니온기를 갖는다. M 1 m＋ 는, 술포닐기를 갖는 술포늄 카티온을 나타낸다. R 001 ∼ R 003 은, 각각 독립적으로 1 가의 유기기를 나타낸다. 단, R 001 ∼ R 003 중, 적어도 1 개는 산 해리성기를 갖는 유기기이다. M 3 m＋ 는, 전자 구인성기를 갖는 m 가의 유기 카티온을 나타낸다. [화학식 1]

Polymerization of bulky norbornene derivatives and polymers obtainable therewith

一种治疗光化性角化病的原料药物巨大戟醇甲基丁烯酸酯的制备方法

一种治疗光化性角化病的原料药物巨大戟醇甲基丁烯酸酯的制备方法，包括下述步骤：原料提取、石油醚萃取、大孔树脂D101吸附干法拌样划段、硅胶分离、Sephadex凝胶纯化、DIOL硅胶纯化。该方法从南欧大戟全草植物分离原料药物巨大戟醇甲基丁烯酸酯，具备分离纯化快捷简单，高效高纯，成本较低等优点。

Reaction products of an olefin, a norbornene and a cyclopentadiene

A product mixture of a norbornene and a tetracyclododecene is prepared in any desired mole ratio in the range of 95/5 to 5/95 which comprises heating an olefin, cyclopentadiene, and a norbornene in the respective mole ratio of 1-20/1-5/1-5, at a temperature of 100° to 400° C., 100 to 5000 psi, and 0.1 to 5 hours of residence time.

Patent JPH0160011B2

2-ETHYL-1,4,5,8-DIMETHANO-1,2,3,4,4a,5,8,8a-OCTAHYDRONAPHTHALENE COMPOSITION FOR POLYMERIZATION AND PROCESS FOR PRODUCING THE SAME

A process for producing a 2-ethyl-1,4,5,8-dimethano-1,2,3,4,4a,5,8,8a-octahydronaphthalene composition in which the total content of two specific cyclopentadiene trimers is 100 to 5,000 ppm, which process comprises reacting cyclopentadiene and/or dicyclopentadiene with 5-ethyl-2-norbornene under specific conditions. By using the composition as a feed material for various kind of polymerization, homogeneous and transparent polymers containing no gel can be obtained.

Plastomers derived from dimethanooctahydronaphthalene and their method of manufacture

THE INVENTION CONCERNS NEW PLASTOMER POLYMERS OBTAINED BY POLYMERISATION OF AT LEAST ONE NEW MONOMER OF THE GROUP OF DIMETHANOOCTAHYDRONAPHTHALENE AND ITS ALKYL DERIVATIVES (OBTAINED BY REACTION OF AN ALIPHATIC OLEFIN WITH CYCLOPENTADIENE) WITH FROM 0 TO 99% OF A COMPOUND OF THE GROUP OF STYRENE, ACENAPHTHYLENE AND CYCLIC OLEFINS, IN THE PRESENCE OF A CATALYST COMPRISING A SALT OF RUTHENIUM, RHODIUM, PALLADIUM, OSMIUM, IRIDIUM, PLATINUM IN ASSOCIATION WITH AN ALCOHOL OR A SALT OF TITANIUM, VANADIUM, ZIRCONIUM, TUNGSTEN, MOLYBDENUM IN ASSOCIATION WITH A COMPOUND HAVING A METAL-HYDROCARBON OR METAL-HYDROCARBON BOND.

STABLE C - (sup3) - CYCLOMETALATED PINCER COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS

The invention relates to a novel class of stable pincer complexes comprising a pinσer ligand linked to the metal via a Calfa cyclometalated carbon and via two donor atoms W1 and W2, wherein said Calfa carbon has a sp3 hybridization; said Calfa carbon is bonded to three Cbeta carbons; each of said Cbeta carbons is linked to the non-hydrogen atoms,- and W1 and W2 are independently selected from P, As, N or O. Said complexes are used as catalyst in transfer hydrogenation reactions such as reduction of ketones, reductions of imines and reductions of olefines.

Polyester resin and method for producing same

Overlapped steric hindrance-enhanced alpha-diimine ligand, nickel catalyst, preparation method and application thereof

本发明提供一类叠加大位阻α‑二亚胺配体、镍催化剂及其制备方法和应用。属于催化剂领域。该配体的结构如式(I)所示。本发明还提供一类叠加大位阻α‑二亚胺配体的制备方法。本发明还提供一种镍催化剂，结构如式(II)所示。本发明还提供一种镍催化剂的制备方法。该类镍催化剂在一定条件下，催化乙烯聚合活性可高达1026.0×10 6 g mol ‑1 h ‑1 ，且可得到超高分子量，支化度可调的聚乙烯。此外，在110～150℃高温下，该类催化剂仍然具有相当高的催化活性。其中，超高分子量低支化度聚乙烯具有良好的工业应用前景，在一定程度上可考虑作为超高分子量聚乙烯纤维使用。

Pleuromuthyline complexes

Large steric hindrance alpha-diimine ligand, nickel catalyst, preparation method and application thereof

本发明涉及一类大位阻α‑二亚胺配体、镍催化剂及其制备方法与应用，属于催化剂技术领域。解决了现有技术中α‑二亚胺催化剂存在的两点问题：1)得到的共聚物分子量很低，一般在一万以下；2)条件比较苛刻，通常需要高温高压。本发明的镍催化剂，结构式如式(II)所示。该镍催化剂具有超大的轴向空间位阻，能够有效地抑制链转移，具有高活性的优点(高达6.9×10 7 gmol ‑1 h ‑1 )，并且在高温下仍然能保持高活性，还具备优异的热稳定性，在常温常压下即可制备得到超高分子量功能化聚烯烃材料。

Large steric hindrance alpha-diimine ligand, nickel catalyst, preparation method and application thereof

本发明涉及一类大位阻α‑二亚胺配体、镍催化剂及其制备方法与应用，属于催化剂技术领域。解决了现有技术中α‑二亚胺催化剂存在的两点问题：1)得到的共聚物分子量很低，一般在一万以下；2)条件比较苛刻，通常需要高温高压。本发明的镍催化剂，结构式如式(II)所示。该镍催化剂具有超大的轴向空间位阻，能够有效地抑制链转移，具有高活性的优点(高达6.9×10 7 gmol ‑1 h ‑1 )，并且在高温下仍然能保持高活性，还具备优异的热稳定性，在常温常压下即可制备得到超高分子量功能化聚烯烃材料。

Compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode

유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치에 관한 것으로, 하기 화학식 1로 표시되는 유기광전자소자용 화합물을 제공하여, 우수한 전기화학적 및 열적 안정성으로 수명 특성이 우수하고, 낮은 구동전압에서도 높은 발광효율을 가지는 유기발광소자를 제조할 수 있다. [화학식 1] The present invention relates to a compound for an organic optoelectronic device, an organic light emitting device including the same, and a display device including the organic light emitting device. The present invention provides a compound for an organic optoelectronic device represented by the following Chemical Formula 1 and having excellent electrochemical and thermal stability, And an organic light emitting device having a high luminous efficiency even at a low driving voltage can be manufactured. [Chemical Formula 1]

Pseudo tröger's base amines and microporous polymers derived from pseudo tröger's base amines

Embodiments of the present disclosure describe carbocyclic pseudo Tröger's base (CTB) amines. Embodiments of the present disclosure further describe microporous polymers derived from pseudo CTB amines, including, but not limited to, polyimides, CTB ladder polymers, and network porous polymers. Other embodiments describe a method of separating chemical species in a fluid composition comprising contacting a microporous polymer membrane with a fluid composition including at least two chemical species, wherein the microporous polymer membrane includes one or more of a ladder polymer of intrinsic microporosity, a microporous polyimide, and a microporous network polymer; and capturing at least one of the chemical species from the fluid composition.

Electroluminescent device

The present invention relates to an electronic device, especially an electroluminescent devices, comprising a compound of Formula (I), especially as host for phosphorescent compounds. The hosts may function with phosphorescent materials to provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

Compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode

유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치에 관한 것으로, 하기 화학식 1로 표시되는 유기광전자소자용 화합물을 제공하여, 우수한 전기화학적 및 열적 안정성으로 수명 특성이 우수하고, 낮은 구동전압에서도 높은 발광효율을 가지는 유기발광소자를 제조할 수 있다. [화학식 1] The present invention relates to a compound for an organic optoelectronic device, an organic light emitting device including the same, and a display device including the organic light emitting device. The present invention provides a compound for an organic optoelectronic device represented by the following Chemical Formula 1 and having excellent electrochemical and thermal stability, And an organic light emitting device having a high luminous efficiency even at a low driving voltage can be manufactured. [Chemical Formula 1]

Synthesis of magnesium adamantane carboxylate and oxide nanocomposite

마그네슘 아다만탄 카복실레이트염의 제조 방법이 제공된다. 상기 방법은 적어도 1종의 카복실산 모이어티를 갖는 다이아몬드형 화합물과 마그네슘염을 혼합하여 반응물 혼합물을 형성시키는 단계 및 반응 온도에서 반응 시간 동안 상기 반응물 혼합물을 열수 처리하여 마그네슘 아다만탄 카복실레이트염을 형성시키는 단계를 포함한다.

Process for the preparation of pleuromutilins

본 발명은, 식 IIa의 화합물 또는 식 IIa의 화합물과 식 IIb의 화합물의 혼합물에서 아민기를 탈보호하고, 반응 혼합물로부터 식 I의 화합물을 분리하는 단계를 포함하는, 식 I의 화합물을 단일한 입체이성질체의 결정 형태로 제조하는 방법; 결정형의 식 I의 화합물 및 화합물의 염; 상기 염을 포함하는 약학 조성물; 식 I의 화합물을 제조하는 공정의 중간산물의 제조 방법과 중간산물을 제공한다.

Chrysenes for deep blue luminescent applications

This disclosure relates to chrysene compounds with deep blue emission that are useful in electroluminescent applications. It also relates to electronic devices in which the active layer includes such a chrysene compound.

Materials for electronic devices

Die vorliegende Anmeldung betrifft ein Polymer,enthaltend mindestens eine Struktureinheit einer Formel (I). Das Polymer eignet sich zur Verwendung in einer elektronischen Vorrichtung.

Compounds that can be used in an organic electronic device as active compounds

The invention relates to compounds that can be used in an organic electronic device as an active compound, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising same.

Organic compound and organic electroluminescent device

一种有机化合物，其特征在于，具有如(1)所示的结构： 其中，L 1 、L 2 和L各自独立的为单键、取代或未取代的C 6 ‑C 30 的亚芳基或者取代或未取代的C 3 ‑C 30 的亚杂芳基；Ar 1 和Ar 2 各自独立的为取代或未取代的C 6 ‑C 60 的芳基、取代或未取代的C 9 ‑C 60 的稠环芳基、取代或未取代的C 3 ‑C 60 的杂芳基或者取代或未取代的C 3 ‑C 60 的稠环杂芳基；R 1 ‑R 4 相同或不同，各自独立的为H、氘、卤素、氰基、硝基、羟基、氨基、取代或未取代的C 1 ‑C 30 的烷基、取代或未取代的C 1 ‑C 30 的烷氧基、取代或未取代的C 3 ‑C 30 的环烷基、取代或未取代的C 3 ‑C 12 的杂环烷基、取代或未取代的C 6 ‑C 30 的芳基、取代或未取代的C 9 ‑C 30 的稠环芳基、取代或未取代的C 3 ‑C 30 的杂芳基或者取代或未取代的C 3 ‑C 30 的稠环杂芳基；其中，R 3 和R 4 可相互连接成环；m、n分别独立地选自1至最大可取的整数。

Compound for organic electronic element, organic electronic element usingthe same, and a electronic device thereof

본 발명은 소자의 발광효율, 안정성 및 수명을 향상시킬 수 있는 신규 화합물 및 이를 이용한 유기전기소자, 그 전자 장치를 제공한다. The present invention provides a novel compound capable of improving luminous efficiency, stability and lifetime of a device, an organic electric device using the same, and an electronic device thereof.

Patent JPS6331450B2

Chrysenes for deep blue luminescent applications

Chrysene compounds for blue or green luminescent applications

本发明涉及用于电致发光应用并且能够发射蓝光或者绿光的䓛化合物。本发明还涉及电子器件，其中的活性层包含此类䓛化合物。

Taxane compounds and also the production method and use thereof

FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to taxane compounds having a structure represented by the following general formula I:where Ris benzoyl, tert-butyloxycarbonyl or N,N'-dimethylcarbamoyl; Ris phenyl,orRis -OMe, -OOCOC, -OCON (CH)or -OCOSCH; Ris -OMe, -OOCOC, -OCON (CH), -OCOSCHor H, wherein Rand Rdo not represent -OM simultaneously; or their pharmaceutically acceptable non-toxic salts or isomers. Also disclosed are taxane compounds of formula II, an anti-tumor pharmaceutical composition, use of taxane compounds and a composition, a method of producing taxane compounds.EFFECT: disclosed taxane compounds have improved oral bioavailability and are characterized by strong cytotoxicity with respect to a number of human cancer cell lines and broad spectrum anti-tumor effects.10 cl, 67 dwg, 23 ex, 6 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) (19) RU (11) (13) 2 686 675 C1 (51) МПК C07D 305/14 (2006.01) C07D 405/12 (2006.01) A61K 31/337 (2006.01) A61K 31/4427 (2006.01) A61P 35/00 (2006.01) A61K 35/02 (2015.01) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/337 (2019.02); A61K 31/4427 (2019.02); C07C 233/87 (2019.02); C07C 271/22 (2019.02); C07D 305/14 (2019.02); C07D 405/12 (2019.02) (21) (22) Заявка: 2016124639, 21.11.2014 (24) Дата начала отсчета срока действия патента: Дата регистрации: 30.04.2019 Приоритет(ы): (30) Конвенционный приоритет: 22.11.2013 CN 201310595107.0 (56) Список документов, цитированных в отчете о поиске: US 20020038038 A1, 28.03.2002. US (45) Опубликовано: 30.04.2019 Бюл. № 13 (86) Заявка PCT: CN 2014/091908 (21.11.2014) (87) Публикация заявки PCT: Адрес для переписки: 123242, Москва, пл. Кудринская, д. 1, а/я 35, "Михайлюк, Сороколат и партнеры патентные поверенные" (54) ТАКСАНОВЫЕ СОЕДИНЕНИЯ, А ТАКЖЕ СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ (57) Реферат: Изобретение относится к таксановым соединениям, имеющим структуру, представленную следующей общей формулой I: R U 2 6 8 6 6 7 5 C ...

Novel Ester Compounds Having Alicyclic Structure and Making Method

본 발명은 하기 화학식 1로 표시되는 에스테르 화합물에 관한 것이다. 본 발명의 에스테르 화합물을 중합함으로써 얻어지는 중합체로 제조된 레지스트 재료는 고에너지선에 감응하고, 기판과의 밀착성, 감도, 해상성, 에칭 내성이 우수하여 전자선 및 원자외선에 의한 미세 가공에 유용하다. 특히, ArF 엑시머 레이저, KrF 엑시머 레이저의 노광 파장에서의 흡수가 작기 때문에 미세하고 나아가 기판에 대하여 수직인 패턴을 쉽게 형성할 수 있으며, 초 LSI 제조용의 미세 패턴 형성 재료로서 적합하다. The present invention relates to an ester compound represented by the following formula (1). The resist material made of the polymer obtained by polymerizing the ester compound of the present invention is sensitive to high energy rays, has excellent adhesion to the substrate, sensitivity, resolution and etching resistance, and is useful for fine processing by electron beams and far ultraviolet rays. In particular, since the absorption at the exposure wavelength of the ArF excimer laser and the KrF excimer laser is small, it is possible to easily form a fine pattern and further perpendicular to the substrate, and is suitable as a fine pattern forming material for ultra LSI production. 식 중, R 1 은 수소 원자 또는 탄소수 1 내지 6의 직쇄상, 분지상 또는 환상의 알킬기를 나타내고, R 2 는 산 불안정기를 나타내며, k는 0 또는 1, m은 0≤m≤5를 만족하는 정수이다. In the formula, R 1 represents a hydrogen atom or a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms, R 2 represents an acid labile group, k represents 0 or 1, and m satisfies 0 ≦ m ≦ 5. Is an integer.

Chrysene for green light emitting applications

Electroluminescent device

The present invention relates to an electronic device, especially an electroluminescent devices, comprising a compound of Formula (I), especially as host for phosphorescent compounds. The hosts may function with phosphorescent materials to provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

Chrysene derivative and organic electroluminescent device using the same

A chrysene derivative shown by the following formula: wherein R 1 to R 10 and R 21 to R 25 are independently a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted cycloalkyl group having 3 to 10 ring carbon atoms, a substituted or unsubstituted alkylsilyl group having 3 to 20 carbon atoms, a substituted or unsubstituted arylsilyl group having 8 to 30 carbon atoms, or a substituted or unsubstituted aryl group having 6 to 20 ring carbon atoms, provided that at least one of R 21 to R 25 is a substituted or unsubstituted fused aromatic ring group having 10 to 20 ring carbon atoms or a substituted or unsubstituted fluorenyl group.

Electroluminescent device

The present invention relates to an electronic device, especially an electroluminescent devices, comprising a compound of Formula (I), especially as host for phosphorescent compounds. The hosts may function with phosphorescent materials to provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

Pleuromutilin complexes

介绍了由以游离碱、酸加成盐或季胺盐型的式I 的截短侧耳素衍生物和环糊精形成的一些络合物和 含此络合物的药物制剂。该络合物可以用络合上述 截短侧耳素和一种适当的环糊精的方法制备，据证明 可以作为药物(如抗生素)，尤其是作为兽药使用，如 以饲料添加剂形式使用。

Bifunctional compound having norbornane skeleton and method for producing same

본 발명에 따르면, 하기 식(1)로 표시되는 이관능성 화합물을 제공할 수 있다. (식 중, R 1 은, COOCH 3 , COOC 2 H 5 , COOC 3 H 7 , COOC 4 H 9 , 또는 CHO를 나타낸다. R 2 는, H, CH 3 또는 C 2 H 5 를 나타낸다.) According to the present invention, it is possible to provide a bifunctional compound represented by the following formula (1). (In the formula, R 1 represents COOCH 3 , COOC 2 H 5 , COOC 3 H 7 , COOC 4 H 9 , or CHO. R 2 represents H, CH 3 or C 2 H 5 .)

Resist composition for immersion exposure, method of forming resist pattern using the same, and fluorine-containing compound

A resist composition for immersion exposure, including a base component (A) that exhibits changed solubility in an alkali developing solution under action of acid, an acid generator component (B) that generates acid upon exposure, and a fluorine-containing compound (C) represented by a general formula (c-1) shown below that is decomposable in an alkali developing solution: wherein R 1 represents an organic group which may contain a polymerizable group, with the proviso that said polymerizable group has a carbon-carbon multiple bond, and the carbon atoms forming the multiple bond are not directly bonded to the carbon atom within the -C(=O)- group in general formula (c-1); and R 2 represents an organic group having a fluorine atom.

Lefamulin intermediate compound and application thereof in preparation of Lefamulin

本发明公开了一种Lefamulin的中间体化合物及其在Lefamulin制备中的应用，以期解决现有技术中Lefamulin制备成本高、收率低的技术问题。本发明提供一种中间体化合物 及其制备方法，并将上述中间体化合物在制备Lefamulin或Lefamulin相关的医药中间体中的应用。本发明克服了现有技术的生产过程中碰到的手性氧化缺乏手性诱导，造成目标化合物转化率非常低、成本非常高、工业化生产困难的缺陷；工业化应用时能够有效降低生产成本，且可以有效控制三废的产生，具有显著的经济效益和社会效益。

Acid Generator, Sulfonic Acid, Sulfonic Acid Derivatives And Radiation-Sensitive Resin Composition

본 발명은 하기 화학식 1i의 구조를 가진 신규한 감방사선성 산발생제를 제공한다. 이 감방사선성 산발생제를 화학 증폭형 감방사선성 수지 조성물에 사용할 경우, 감방사선성 산발생제는 높은 투명성 및 비교적 높은 가연성을 나타내며 인체 축적성에 문제가 없으며, 발생하는 산의 산성도 및 비점이 높고, 레지스트 피막 중에서의 확산 길이가 적당히 짧으며 마스크 패턴 밀도에 대한 의존성이 낮다. The present invention provides a novel radiation-sensitive acid generator having a structure of Formula 1i. When the radiation-sensitive acid generator is used in a chemically amplified radiation-sensitive resin composition, the radiation-sensitive acid generator has high transparency and relatively high flammability and has no problem in human accumulation, and the acidity and boiling point of acid generated High, the diffusion length in the resist film is moderately short, and the dependence on the mask pattern density is low. <화학식 1i> <Formula 1i> 식 중, R은 불소 함유율이 50 중량％ 이하인 1가의 유기기, 니트로, 시아노기 또는 수소 원자를 나타내고, Z 1 및 Z 2 는 서로 독립적으로 불소 원자 또는 탄소수 1 내지 10의 직쇄상 또는 분지상의 퍼플루오로알킬기를 나타낸다. In the formula, R represents a monovalent organic group, nitro, cyano group or hydrogen atom having a fluorine content of 50% by weight or less, and Z 1 and Z 2 are each independently a fluorine atom or a linear or branched carbon atom having 1 to 10 carbon atoms. Perfluoroalkyl group is represented. 산발생제, 감방사선성 수지 조성물, 알칼리 가용성 수지, 술폰산 Acid generator, radiation sensitive resin composition, alkali soluble resin, sulfonic acid

Pharmaceutical compositions with reduced release of phenol opioids

FIELD: medicine, pharmaceutics. SUBSTANCE: group of inventions relates to medicine and deals with a pharmaceutical composition for the treatment or prevention of pain or for the reduction of potential abuse with phenol opioids, which contains a trypsin inhibitor and a compound, containing a residue of phenol opioid. The group of inventions also deals with a method of treatment and prevention of pain in a patient, requiring such treatment, which includes the introduction to the patient of an effective quantity of the said pharmaceutical composition; application of the said pharmaceutical composition in manufacturing a medication for the treatment or prevention of pain; method of reducing potential abuse with phenol opioid, including a combination of a prodrug of the phenol opioid, which provides the enzymatically-controlled release of the phenol opioid with an enzyme inhibitor. EFFECT: group of inventions provides the treatment or prevention of pain and reduction of potential abuse with phenol opioids. 51 cl, 9 dwg, 9 tbl, 20 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 562 583 C2 (51) МПК A61K 31/395 (2006.01) A61K 31/485 (2006.01) A61P 29/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011119643/15, 16.10.2009 (24) Дата начала отсчета срока действия патента: 16.10.2009 Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): ДЖЕНКИНС Томас Э. (US), СЕРУДЖИ Джули Д. (US), РЭЙ Джонатан В. (US) 17.10.2008 US 61/106,400 (43) Дата публикации заявки: 27.11.2012 Бюл. № 33 R U (73) Патентообладатель(и): СИГНИЧЕР ТЕРАПЬЮТИКС, ИНК. (US) (45) Опубликовано: 10.09.2015 Бюл. № 25 C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 17.05.2011 (86) Заявка PCT: 2 5 6 2 5 8 3 US 2009/061068 (16.10.2009) R U 2 5 6 2 5 8 3 (56) Список документов, цитированных в отчете о поиске: WO 2007/140272 A2, 06.12.2007. US 20030035831 A1, 20.02.2003. RU 2166512 C2, 10.05.2001. US 20070123468 A1, 31.05.2007 ...

Positive photoresist composition containing alicyclic dissolution inhibitors

폴리머, 광활성제, 및 다음 화학식 (1)로 표현되는 용해 억제제를 포함하는 포지티브 포토레지스트 조성물: A positive photoresist composition comprising a polymer, a photoactive agent, and a dissolution inhibitor represented by the following general formula (1): 상기 화학식 (1)에서 R 1 및 R 2 는 각각 독립적으로 히드록실기, C 1-8 히드록시알킬기, 또는 C 3-8 히드록시시클로알킬기이고; R 3 , R 4 및 R 5 는 각각 독립적으로 수소, C 1-8 히드록시알킬기, C 1-6 카르복실산 또는 C 3-8 카르복실산 에스테르이고; k는 0, 1, 2, 3, 4, 5 또는 6 인 정수이다. 본 발명의 포토레지스트 조성물은 KrF와 ArF 엑시머레이저로부터의 원자외선 (deep UV)에 노출될 때 화학적으로 증폭된 형태의 레지스트로서 유용하다. R 1 and R 2 in the formula (1) are each independently a hydroxyl group, a C 1-8 hydroxyalkyl group, or a C 3-8 hydroxycycloalkyl group; R 3 , R 4 and R 5 are each independently hydrogen, a C 1-8 hydroxyalkyl group, C 1-6 carboxylic acid or C 3-8 carboxylic acid ester; k is an integer equal to 0, 1, 2, 3, 4, 5 or 6. The photoresist compositions of the invention are useful as chemically amplified forms of resist when exposed to deep UV from KrF and ArF excimer lasers. 폴리머, 광활성제, 용해 억제제, 포지티브 포토레지스트, 리소그래피 Polymers, Photoactive Agents, Dissolution Inhibitors, Positive Photoresists, Lithography

Taxane compounds and also the production method and use thereof

FIELD: medicine; pharmaceuticals.SUBSTANCE: invention relates to taxane compounds having a structure represented by the following general formula I:where Ris benzoyl, tert-butyloxycarbonyl or N,N'-dimethylcarbamoyl; Ris phenyl,orRis -OMe, -OOCOC, -OCON (CH)or -OCOSCH; Ris -OMe, -OOCOC, -OCON (CH), -OCOSCHor H, wherein Rand Rdo not represent -OM simultaneously; or their pharmaceutically acceptable non-toxic salts or isomers. Also disclosed are taxane compounds of formula II, an anti-tumor pharmaceutical composition, use of taxane compounds and a composition, a method of producing taxane compounds.EFFECT: disclosed taxane compounds have improved oral bioavailability and are characterized by strong cytotoxicity with respect to a number of human cancer cell lines and broad spectrum anti-tumor effects.10 cl, 67 dwg, 23 ex, 6 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 686 675 C9 (51) МПК C07D 305/14 (2006.01) C07D 405/12 (2006.01) A61K 31/337 (2006.01) A61K 31/4427 (2006.01) A61P 35/00 (2006.01) A61K 35/02 (2015.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) СКОРРЕКТИРОВАННОЕ ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ Примечание: библиография отражает состояние при переиздании (52) СПК A61K 31/337 (2019.02); A61K 31/4427 (2019.02); C07C 233/87 (2019.02); C07C 271/22 (2019.02); C07D 305/14 (2019.02); C07D 405/12 (2019.02) (21)(22) Заявка: 2016124639, 21.11.2014 21.11.2014 (73) Патентообладатель(и): ЦЗЯНСУ ТАСЛИ ДИИ ФАРМАСЬЮТИКАЛ КО., ЛТД. (CN) 22.11.2013 CN 201310595107.0 (45) Опубликовано: 30.04.2019 Версия коррекции №1 (W1 C1) (48) Коррекция опубликована: C 9 26.09.2019 Бюл. № 27 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 22.06.2016 (86) Заявка PCT: R U 2 6 8 6 6 7 5 CN 2014/091908 (21.11.2014) (87) Публикация заявки PCT: WO 2015/074605 (28.05.2015) Адрес для переписки: 123242, Москва, пл. Кудринская, д. 1, а/я 35, "Михайлюк, Сороколат и партнеры патентные поверенные" (54) ТАКСАНОВЫЕ СОЕДИНЕНИЯ, А ТАКЖЕ СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ (57 ...

Amine based compound and organic light emitting device comprising the same

본 명세서는 아민계 화합물 및 이를 포함하는 유기 발광 소자를 제공한다.

Compound for organic electronic element, organic electronic element usingthe same, and a electronic device thereof

본 발명은 소자의 발광효율, 안정성 및 수명을 향상시킬 수 있는 신규 화합물 및 이를 이용한 유기전기소자, 그 전자 장치를 제공한다.

Pharmaceutical for treatment of neurological and neuropsychiatric disorders

The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Pharmaceutical preparation for the treatment of neurological and neuropsychiatric disorders

Amine based compound and organic light emitting device comprising the same

본 명세서는 아민계 화합물 및 이를 포함하는 유기 발광 소자를 제공한다. The present invention provides an amine compound and an organic light emitting device comprising the same.

Salt and photoresist composition containing the same

A salt represented by the formula (I-CC): wherein Q 1 and Q 2 each independently represent a fluorine atom etc., X 1 represents a single bond etc., Y 1 represents a C1-C36 aliphatic hydrocarbon group etc., A 1 and A 2 independently each represents a C1-C20 aliphatic hydrocarbon group etc., Ar 1 represents a (m 4 +1)-valent C6-C20 aromatic hydrocarbon group which can have one or more substituents, B 1 represents a single bond etc., B 2 represents a group capable of being eliminated by the action of an acid, m 1 and m 2 independently each represents an integer of 0 to 2, m 3 represents an integer of 1 to 3, with the proviso that m 1 plus m 2 plus m 3 equals 3, and m 4 represents an integer of 1 to 3, and a photoresist composition comprising the salt represented by the formula (I-CC) and a resin comprising a structural unit having an acid-labile group and being insoluble or poorly soluble in an aqueous alkali solution but becoming soluble in an aqueous alkali solution by the action of an acid.

Salt and photoresist composition containing the same

A salt represented by the formula (I-CC): wherein Q 1 and Q 2 each independently represent a fluorine atom etc., X 1 represents a single bond etc., Y 1 represents a C1-C36 aliphatic hydrocarbon group etc., A 1 and A 2 independently each represents a C1-C20 aliphatic hydrocarbon group etc., Ar 1 represents a (m 4 +1)-valent C6-C20 aromatic hydrocarbon group which can have one or more substituents, B 1 represents a single bond etc., B 2 represents a group capable of being eliminated by the action of an acid, m 1 and m 2 independently each represents an integer of 0 to 2, m 3 represents an integer of 1 to 3, with the proviso that m 1 plus m 2 plus m 3 equals 3, and m 4 represents an integer of 1 to 3, and a photoresist composition comprising the salt represented by the formula (I-CC) and a resin comprising a structural unit having an acid-labile group and being insoluble or poorly soluble in an aqueous alkali solution but becoming soluble in an aqueous alkali solution by the action of an acid.

Pleuromutilin compounds for treating bacterial infectious diseases

本发明涉及新型截短侧耳素类化合物、它们的药物组合物及使用方法。此外，本发明还涉及用于治疗细菌感染的治疗方法，包括耐药性微生物造成的感染，包括多重耐药性微生物。

Novel Ester Compounds, Polymers, Resist Materials and Process for Forming Pattern

하기 화학식 1a로 표시되는 에스테르 화합물을 구성 단위로서 함유하는 중량평균 분자량 1,000 내지 500,000의 고분자 화합물. A polymer compound having a weight average molecular weight of 1,000 to 500,000 containing an ester compound represented by the following formula (1a) as a structural unit. 식 중, In the formula, R 1 은 수소 원자, 메틸기 또는 CH 2 CO 2 R 14 를 나타내고, R 1 represents a hydrogen atom, a methyl group or CH 2 CO 2 R 14 , R 2 는 수소 원자, 메틸기 또는 CO 2 R 14 를 나타내고, R 2 represents a hydrogen atom, a methyl group or CO 2 R 14 , R 3 은 탄소수 1 내지 8의 직쇄상, 분지상 또는 환상의 알킬기 또는 탄소수 6 내지 20의 치환될 수 있는 아릴기를 나타내고, R 3 represents a linear, branched or cyclic alkyl group having 1 to 8 carbon atoms or an aryl group which may be substituted with 6 to 20 carbon atoms, R 4 내지 R 13 은 각각 독립적으로 수소 원자 또는 탄소수 1 내지 15의 헤테로 원자를 포함할 수 있는 1가의 탄화수소기를 나타내고, 서로 환을 형성할 수 있으며, 그 경우에는 탄소수 1 내지 15의 헤테로 원자를 포함할 수 있는 2가의 탄화수소기를 나타내고, R 4 to R 13 each independently represent a hydrogen atom or a monovalent hydrocarbon group which may include a hetero atom having 1 to 15 carbon atoms, and may form a ring with each other, in which case include a hetero atom having 1 to 15 carbon atoms Represents a divalent hydrocarbon group, 또한, R 4 내지 R 13 은 인접하는 탄소에 결합하는 것 끼리 아무것도 개재하지 않고 결합하며, 2중 결합을 형성할 수 있고, In addition, R 4 to R 13 may be bonded to each other without bonding between adjacent carbons, may form a double bond, R 14 는 탄소수 1 내지 15의 직쇄상, 분지상 또는 환상의 알킬기를 나타낸다. R 14 represents a linear, branched or cyclic alkyl group having 1 to 15 carbon atoms. 본 발명의 고분자 화합물을 기재 수지로한 레지스트 재료는 고에너지선에 감응하고, 감도, 해상성, 엣칭 내성이 우수하기 때문에, 전자선이나 원자외선에 의한 미세가공에 유용하다. ArF 엑시머 레이저, KrF 엑시머 레이저의 노광 파장에서의 흡수가 작기 때문에, 미세하고 또한 기판에 대하여 수직인 패턴을 용이하게 형성할 수 있다. Since the resist material using the polymer compound of the present invention as a base resin is sensitive to high energy rays and excellent in sensitivity, resolution, and etching resistance, it is useful for microfabrication by electron beam or far ultraviolet rays. Since the absorption at the exposure wavelength of the ArF excimer laser ...

New process for producting pleuromutilin derivatives

Steviol glycoside isomers

FIELD: chemistry. SUBSTANCE: invention relates to compounds of formula II: where R 1 can be 1-β-D-glucopyranosyl or 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, and R 2 can be hydrogen, 1-β-D-glucopyranosyl, 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2,3-bis(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, or 2-(1-β-D-xylopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl. EFFECT: compounds can be used as sweetening agents which do not have nutritional qualities in food and drinks. 35 cl, 8 ex, 23 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 430 102 (13) C1 (51) МПК C07H C07H C07C A23L A23L 15/24 13/08 62/32 1/236 2/60 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2010107991/04, 04.09.2008 (24) Дата начала отсчета срока действия патента: 04.09.2008 (73) Патентообладатель(и): ПепсиКо, Инк. (US) R U Приоритет(ы): (30) Конвенционный приоритет: 17.09.2007 US 11/856,274 (72) Автор(ы): ЛЕЕ Томас (US) (45) Опубликовано: 27.09.2011 Бюл. № 27 C 1 2 4 3 0 1 0 2 R U C 1 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 05.03.2010 (86) Заявка PCT: US 2008/075192 (04.09.2008) (87) Публикация заявки РСТ: WO 2009/038978 (26.03.2009) Адрес для переписки: 127006, Москва, ул. Долгоруковская, 7, Садовая Плаза, 11 этаж, фирма "Бейкер и Макензи", патентному поверенному Ю.А.Пыльневу (54) ИЗОМЕРЫ СТЕВИОЛ-ГЛИКОЗИДОВ (57) Реферат: Данное изобретение соединениям формулы II относится к Ñòð.: 1 ru 2 4 3 0 1 0 2 (56) Список документов, цитированных в отчете о поиске: М. Kobayashi et al, "Dulcosides A and B, new diterpene glycosides from Stevia Rebaudiana", Phytochemistry, 1977, v.16, pp.1405-1408. Hanson J.R. et al, "The microbiological transformation of steviol derivatives by rhizopus stolinifer and gibberella fujikuroi", ...

Salt for acid generator and chemically amplified resist composition

Functional norbornanyl ester derivatives, polymers and process for preparing same

本发明涉及一种新的功能性降冰片酯衍生物和/或聚合物组成,该功能性降冰片酯衍生物和/或聚合物可以方便地通过由相应的二烯烃和二烯亲和物所得到的狄尔斯‑阿尔德反应加成物与羧酸进行反应来制备。本发明主要涉及一种生产环状化工原料的新方法,这种环状化工原料可用于制造涂料，油墨，粘合剂，增塑剂,热塑性或热固性塑料和功能性聚合物。

Taxanes compounds, preparation method therefor, and uses thereof

본 발명은 경구 항종양 치료제의 제조에 있어서 화학식 (I) 또는 화학식 (II) 구조를 갖는 탁산 화합물, 상기 화합물의 제조 방법, 상기 화합물, 이들의 약학적으로 허용가능한 염 및 용매화물을 활성 성분으로 함유하는 조성물의 용도를 제공한다. 화학식 (I)에서, R 1 은 -COR 6 , -COOR 6 또는 -CONR 7a R 7b 이고; R 2 는 C1-C6 알킬, C1-C6 알케닐, 치환된 탄화수소기, 헤테로시클릴기, 방향족기 또는 치환된 방향족기이며; R 3 는 -OR 6 , -OCOOR 6 , -OCOSR 6 또는 -OCONR 7a R 7b 이고; R 4 는 -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b 또는 H이며; 상기 R 6 는 C1-C6 알킬, C1-C6 알케닐, C1-C6 알키닐, 치환된 탄화수소기, 방향족기 또는 헤테로시클릴기이고; R 7a 및 R 7b 는 각각 수소, 탄화수소기, 치환된 탄화수소기 또는 헤테로시클릴기이다. 화학식 (II)에서, R 1 은 -COR 6 또는 -COOR 6 이고; R 2 는 방향족기이며; R 3 는 -OR 6 이고; 상기 R 6 는 C1-C6 알킬, C1-C6 알케닐, C1-C6 알키닐, 치환된 탄화수소기, 방향족기 또는 헤테로시클릴기이다. The present invention provides a taxane compound having the structure of Formula (I) or Formula (II), a method for preparing the compound, and a pharmaceutically acceptable salt and solvate thereof for the preparation of an oral antitumor therapeutic agent as an active ingredient The use of the composition containing it is provided. In formula (I), R 1 is -COR 6 , -COOR 6 or -CONR 7a R 7b ; R 2 is C1-C6 alkyl, C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclyl group, an aromatic group or a substituted aromatic group; R 3 is -OR 6 , -OCOOR 6 , -OCOSR 6 or -OCONR 7a R 7b ; R 4 is -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b or H; wherein R 6 is C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclyl group; R 7a and R 7b is each hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclyl group. In formula (II), R 1 is -COR 6 or -COOR 6 ; R 2 is an aromatic group; R 3 is —OR 6 ; and R 6 is C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group, or a heterocyclyl group.

Heterocyclic compound and organic light emitting device comprising same

본 명세서는 화학식 1로 표시되는 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자에 관한 것이다.

Isomers of Steviol Glycosides

1. Соединение по формуле II:в котором Rявляется водородом, a Rявляется 2-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, 2,3-бис(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, 2-(1-α-L-рамнопиранозил)-1-β-D-глюкопиранозилом, 2-(1-α-L-рамнопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, или 2-(1-β-D-ксилопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.2. Соединение по п.1, в котором Rявляется 2-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.3. Соединение по п.1, в котором Rявляется 2,3-бис(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.4. Соединение по п.1, в котором Rявляется 2-(1-α-L-рамнопиранозил)-1-β-D-глюкопиранозилом.5. Соединение по п.1, в котором Rявляется 2-(1-α-L-рамнопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.6. Соединение по п.1, в котором Rявляется 2-(1-β-D-ксилопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.7. Соединение по п.1, в котором соединение является выделенным и очищенным.8. Питьевой продукт, содержащий:водосодержащую жидкость, исоединение по формуле II:в котором Rявляется водородом, a Rявляется 2-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, 2,3-бис(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, 2-(1-α-L-рамнопиранозил)-1-β-D-глюкопиранозилом, 2-(1-α-L-рамнопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом, или 2-(1-β-D-ксилопиранозил)-3-(1-β-D-глюкопиранозил)-1-β-D-глюкопиранозилом.9. Питьевой продукт по п.8, выбранный из группы, состоящей из газированных напитков, негазированных напитков, напитков, приготовляемых автоматами, замороженных газированных напитков, порошковых концентратов, сухих концентратов, фруктовых соков, ароматизированных напитков с фруктовым соком, напитков с фруктовым ароматом, спортивных напитков, энергетических напитко� РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2011 124 563 (13) A (51) МПК C07H C07H C07C A23L A23L 15/24 13/08 62/32 1/236 2/60 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21 ...

TAXANIC COMPOUNDS, AND ALSO THE WAY OF THEIR OBTAINING AND THEIR APPLICATION

А 2016124639 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ 19 1] 3 о < < ма = эх (13 7 ВИ‘? за 5 43а 630 А (50) МПК 07) 305/74 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2016124639, 21.11.2014 (71) Заявитель(и): | ЦЗЯНСУ ТАСЛИ ДИИ Приоритет(ы): ФАРМАСЬЮТИКАЛ КО. ЛТД. (СЮ) (30) Конвенционный приоритет: 22.11.2013 СМ 201310595107.0 (72) Автор(ы): , ЧЖОУ Вэй (СМ), (43) Дата публикации заявки: 27.12.2017 Бюл. №36 ЦЗИН Юньжун (СЮ), (85) Дата начала рассмотрения заявки РСТ на ВАН Юнфэн (СЮ, национальной фазе: 22.06.2016 ВАН Гочэн (СМ) (86) Заявка РСТ: СМ 2014/091908 (21.11.2014) (87) Публикация заявки РСТ: \О 2015/074605 (28.05.2015) Адрес для переписки: 123242, Москва, пл. Кудринская, д. 1, а/я 35, "Михайлюк, Сороколат и партнеры - патентные поверенные" (54) ТАКСАНОВЫЕ СОЕДИНЕНИЯ, АТАКЖЕ СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ (57) Формула изобретения 1. Таксановые соединения, имеющие структуру, представленную следующей общей формулой Г: &: о в В-нн о во - - О бн н@б 3 о | —& 2 |, где К! представляет собой -СОВ, -СООВк или -СОМЕВл.Кль; К› представляет собой С1-Сбалкил, С1-Сбалкенил, замещенную углеводородную группу, гетероциклическую группу, ароматическую группу или замещенную ароматическую группу; В. представляет собой -ОВб, -ОСООВк, -ОСОЗВ 6 или -ОСОМВл.Вль; В. представляет собой -ОВк, -ОСООВ, -ОСОЗВ в, -ОСОМКл.Вль или Н; где Кс представляет собой С1-Сбалкил, С1-Сбалкенил, С1-Сбалкинил, замещенную углеводородную группу, ароматическую группу или гетероциклическую группу; Кл. и Стр.: 1 па 6$ ЭС 9рОсС У А 2016124639 ко Кль представляют собой водород, углеводородную группу, замещенную углеводородную группу или гетероциклическую группу. 2. Таксановые соединения по п. 1, где К, представляет собой бензоил, трет-бутилоксикарбонил или №,М'-диметилкарбамоил; К> представляет собой фенил, | | АА К. представляет собой -ОМЬ, -ОСООСНЗ, -ОСОМ(СН-)> или -ОСОЗС>Н5; К. представляет собой -ОМе, -ОСООСНф, -ОСОМ(СН-)>, -ОСОЗС>Н5 или Н. 3. 'Таксановые ...

Process for the preparation of pleuromutilins

본 발명은, 식 IIa의 화합물 또는 식 IIa의 화합물과 식 IIb의 화합물의 혼합물에서 아민기를 탈보호하고, 반응 혼합물로부터 식 I의 화합물을 분리하는 단계를 포함하는, 식 I의 화합물을 단일한 입체이성질체의 결정 형태로 제조하는 방법; 결정형의 식 I의 화합물 및 화합물의 염; 상기 염을 포함하는 약학 조성물; 식 I의 화합물을 제조하는 공정의 중간산물의 제조 방법과 중간산물을 제공한다. The present invention relates to a process for the preparation of a compound of formula I by deprotecting an amine group in a mixture of a compound of the formula IIa or a compound of the formula IIa and a compound of the formula IIb and isolating the compound of the formula I from the reaction mixture, In the form of an isomeric crystal form; Salts of compounds and compounds of formula I in crystalline form; A pharmaceutical composition comprising said salt; A process for the preparation of an intermediate product of the process for preparing a compound of formula I and an intermediate product are provided.

Novel tertiary alcohol compounds having alicyclic structure

Tertiary alcohol compounds of formula (1) are novel wherein R 1 and R 2 are C1-10 alkyl groups which may have halogen substituents, or R 1 and R 2 may form an aliphatic hydrocarbon ring, Y and Z are a single bond or a divalent C1-10 organic group, and k=0 or 1. Using the tertiary alcohol compounds as a monomer, polymers are obtained. A resist composition comprising the polymer as a base resin is sensitive to high-energy radiation and has excellent sensitivity, resolution, etching resistance and substrate adhesion.

Chrysene compounds for blue or green luminescent applications

This invention relates to chrysene compounds that are useful in electroluminescent applications and are capable of blue or green emission. It also relates to electronic devices in which the active layer includes such a chrysene compound.